Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3530675 | 0.88 | P2RX7 (0.38) | MAPK14P2RX7KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL3530836 | 0.85 | HSD11B1 (0.46) | P2RX7SMN1; SMN2HTR2AHTR2C | |
| SCHEMBL3530690 | 0.84 | HSD11B1 (0.43) | MAPK14P2RX7KDM4EALDH1A1HTR2A | |
| SCHEMBL3535746 | 0.80 | HSD11B1 (0.48) | MAPK14SMN1; SMN2HTR2A | |
| SCHEMBL3530514 | 0.80 | P2RX7 (0.40) | P2RX7KDM4ESMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL3533829 | 0.79 | L3MBTL1 (0.34) | MAPK14P2RX7 | |
| SCHEMBL3535544 | 0.78 | HSD11B1 (0.56) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL3534235 | 0.75 | HSD11B1 (0.39) | SMN1; SMN2ALDH1A1HTR2AHTR2C | |
| SCHEMBL3530595 | 0.74 | HSD11B1 (0.41) | KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL3526953 | 0.74 | HSD11B1 (0.51) | P2RX7HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652057-B2 | Pyrazolones as 11b-HSD1 inhibitors for diabetes | HOFFMAN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| EP-1924562-A2 | PYRAZOLONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007025880-A2 | PYRAZOLONE DERIVATIVES AS 11-BETA HSD1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049574-A1 | New pyrazolones as 11b-HSD1 inhibitors for diabetes | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049574-A1 | New pyrazolones as 11b-HSD1 inhibitors for diabetes | HSD11B1, HSD17B1, HSD17B7 | MAPK14 928/4885P2RX7 2161/4885KDM4E 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.